NFO Insight: Baroda BNP Paribas Health and Wellness Fund opens. Is it the right prescription for your portfolio?
's latest
new fund offer
, the
Baroda BNP Paribas Health and Wellness Fund
, is open for subscription and will close on June 23. This open-ended equity scheme will focus on companies expected to benefit from the rising demand in
healthcare
and wellness—an emerging megatrend both in India and globally.
The fund aims to capitalise on the multi-decade structural growth story within the healthcare and wellness space.
CEO comments on fund launch
Best MF to invest
Looking for the best mutual funds to invest? Here are our recommendations.
View
Details
»
'Over the last century, average life expectancy in India has more than tripled. Across every life stage—from toddler to septuagenarian—there is a constant need and expenditure towards well-being. Given the low starting base of per capita healthcare spending, we view this sector as a multi-decadal opportunity offering promising prospects for investors,' said Suresh Soni, CEO, Baroda BNP Paribas AMC.
Also Read |
Lumpsum vs SIP: Is caution killing the case for lumpsum?
CIO on fund launch
Live Events
'India offers a $200 billion market cap opportunity with over 100 investible companies across pharma, diagnostics, Medtech, hospitals, insurance, and healthcare research,' said Sanjay Chawla, CIO – Equity, Baroda BNP Paribas AMC.
The primary objective of the scheme is to provide long-term capital appreciation by investing predominantly in equity and equity-related instruments of pharma and healthcare companies.
The fund will be benchmarked against the BSE Healthcare Total Return Index and will be managed by Sanjay Chawla.
This thematic fund is suited for investors with an investment horizon of three years or more. It offers an opportunity to participate in India's growing health consciousness and invest in an evolving ecosystem of wellness-focused businesses.
Sector Expected to Grow
While India's current per capita healthcare expenditure is significantly lower than that of developed markets, it is expected to grow exponentially. Key drivers include rising affordability, increasing awareness, longer life expectancy, and a higher incidence of chronic diseases, according to a press release.
Experts' Take on the New Launch
Experts typically advise caution when it comes to investing in New Fund Offers (NFOs), unless the scheme offers something genuinely unique—such as access to an untapped investment theme or an enhanced proposition over existing options. Without a historical performance record, investors may find it difficult to make informed decisions.
According to one expert, there are already over 10 pharma and healthcare-focused
mutual funds
available in the market. However, this new fund may adopt a distinct approach in terms of stock selection, portfolio construction, or focus on sub-segments like diagnostics, CDMOs, wellness, or healthcare services—potentially offering a fresh perspective within the broader theme.
'As with any new fund, it does not yet have a performance track record. So, while the investment philosophy might be compelling, it's sensible to monitor how the portfolio evolves and how the fund navigates different market conditions,' said Sagar Shinde, VP of Research at Fisdom, in a note to ETMutualFunds.
Also Read |
Mutual funds reduces overall cash allocation by Rs 6,200 crore to Rs 2.17 lakh crore in May
'There's no pressing need to rush into the
NFO
. Given the ample choices already available in this category with proven track records, it's better to wait, watch how this fund shapes up, and then consider it for investment based on merit,' Shinde added.
Another expert shares a different opinion on this new fund as she mentions that Baroda BNP Paribas Health and Wellness Fund is not the first of its kind in India as several healthcare and pharma-focused funds are already in the market but what differentiates each fund is its investment approach, stock selection, and how broadly it defines the healthcare ecosystem—some include wellness, diagnostics, hospitals, and even health-tech platforms.
'Baroda BNP Paribas fund offers investors another opportunity to tap into India's growing healthcare story. It's worth considering for those looking to increase sectoral exposure, especially from a long-term perspective. Like any sectoral fund, it should be evaluated based on investment horizon, portfolio strategy, and alignment with personal financial goals,' Shruti Jain, Chief Strategy Officer, Arihant Capital Markets shared exclusively with ETMutualFunds.
The minimum amount for lump sum investment is Rs 1,000 and in multiples of Re 1 thereafter. For Systematic Investment Plans with daily, weekly, or monthly frequency, the minimum SIP amount is Rs 500 and in multiples of Re 1 thereafter; for quarterly SIPs, the minimum amount is Rs 1,500 and in multiples of Re 1 thereafter.
The fund will allocate 80–100% in equity and equity-related instruments of companies in the pharma, healthcare, and allied sectors; 0–20% in equity and equity-related instruments of companies other than those in the pharma, healthcare, and allied sectors; 0–20% in debt and money market instruments; 0–10% in units of mutual funds (domestic schemes); and 0–10% in units issued by REITs and InvITs.
Time to allocate in this sector?
Shinde advises that in pharma, recent corrections have created better entry points, and the long-term structural drivers remain intact. Staggered investments can be considered.
On the other hand, Jain mentions that pharma and healthcare remain strong thematic plays, particularly because they offer defensive qualities in uncertain markets. Given India's demographic trends—rising average age, increasing healthcare awareness, and lifestyle-related health issues—this sector is poised for long-term structural growth.
'Investors who do not currently have any exposure to this space may consider allocating around 10% of their total equity portfolio to healthcare and pharma funds. However, this should be done with a minimum 3–5 year investment horizon and as part of a well-diversified portfolio. A staggered investment approach (via SIP or tranches) can also help manage entry-point risk,' Jain advises investors.
Apart from Baroda BNP Paribas Health and Wellness Fund, there are 16 funds based on the pharma and healthcare sector, of which 10 have a track record of three years in the market.
ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund offered the highest return of around 29.05% in the last three years, followed by
SBI Healthcare Opp Fund
, which has offered a 28.36% return in the same time period. LIC MF Healthcare Fund gave the lowest return of around 20.77% in the said period.
With enough funds based on the sector and having a long performance track record, Shinde mentions that the outlook is neutral to positive overall but very constructive on hospitals and specialty pharma segments. While U.S. pricing pressure remains a concern, domestic demand, growth in chronic therapies, and export diversification are supportive.
In the last three years, these funds have offered an average return of 24.72%, and in the last five years, they have delivered an average return of 21.93%, with up to 25.16% return in the last five years. LIC MF Healthcare Fund gave the lowest return in the last five years at around 17.40%.
Jain believes that the long-term outlook for India's pharma and healthcare sector remains robust. Post-COVID, there has been a fundamental shift in consumer behaviour and government focus toward healthcare infrastructure, wellness, and preventive care. India's role as a global pharmaceutical manufacturing hub and growing domestic demand support the sector's earnings potential.
'While short-term volatility may persist due to regulatory changes or global market sentiment, the structural drivers remain intact. Innovation in biosimilars, rising export demand, growth in diagnostics and hospitals, and increasing insurance penetration further strengthen the investment case. As such, this sector offers a compelling mix of growth and defensiveness, making it a relevant thematic allocation for long-term investors,' she added.
One should always invest based on their risk appetite, investment horizon, and goals.
(
Disclaimer
: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)
If you have any mutual fund queries, message ET Mutual Funds on Facebook/Twitter. We will get it answered by our panel of experts. Do share your questions on
ETMFqueries@timesinternet.in
along with your age, risk profile, and Twitter handle.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 days ago
- Time of India
Equity fund launches slow down in 2025 amid stock market uncertainty
Live Events Agencies Mumbai: Equity fund launches by mutual funds experienced a slowdown in 2025, following a blockbuster 2024, as uncertainty over the stock market outlook and losses in many of last year's new fund offerings dimmed investor appetite for fresh products. In the first half of 2025, ending June 30, mutual funds launched 29 open-ended equity schemes, mobilising ₹12,543 crore as against 37 schemes that collected ₹38,655 crore in the same period of 2024 and 44 that garnered close to ₹56,000 crore in the second half of last year, as per Association of Mutual Funds in India moderation in new fund launches this year, compared to CY 2024, could be due to the equity markets being relatively flat for the last 12 months, with increased volatility in the last few months, said Suresh Soni, CEO, Baroda BNP Paribas Mutual Fund."We may see the number of new funds, especially from older fund houses, taper off as they have completed the themes and strategies that they wanted to offer to investors," he the entire year, 2024 witnessed 81 equity new fund offers (NFOs) led by thematic funds , collectively garnering ₹94,548 crore, riding the bullish wave in the stock market till funds raised record money from investors through new fund offers (NFOs) in segments like defence, tourism, capital markets, energy, manufacturing, innovation, transportation and logistics, automotive, internet economy, realty, and many others. As regulations prevent fund houses from operating more than one scheme in each equity category, the industry has found a way around the rule by launching schemes based on various themes. Moreover, various mutual funds launched schemes to reward distributors, who often push investors to shift from products that investors held for a while to new equity funds that charge higher returns of many sectoral and thematic funds swinging wildly after the sell-off between October and March and the subsequent rebound, investors have been unnerved by the volatility, resulting in their demand for new products going Bagla, CEO of Trust MF, attributed the fall in NFOs to geopolitical challenges in the first half of this year. "The markets had turned volatile at the beginning of the year, which dented investor sentiment for some time. Also, slowing growth and Trump tariffs slowed the flows down a bit."In January-March of 2025, mutual funds saw 20 schemes raise ₹7,853 crore, while April-June saw nine schemes collect ₹4,690 crore. Muted returns have also made fund houses hesitant to launch new schemes. According to Value Research, the large-cap equity funds category delivered only 5% returns in the first six months of 2025, while the large-and-mid-cap category returned just 1%.Bagla said investor interest is likely to revive soon with newer mutual funds starting operations."There will a spate of sectoral and thematic fund launches by newer mutual funds," he said. "However, I expect the current year's mobilisation numbers to be a tad less than last year's as the current equity performance is not as strong as last year's."
Mint
6 days ago
- Mint
Best mutual funds: THESE large cap schemes gave over 20% annualised return in past 3 years
Before investing in a mutual fund scheme, it is vital to examine the past returns of that scheme and compare the same with similar schemes in the same category. For instance, if an investor wants to invest in a large cap mutual fund, it is recommended to compare the past few years' returns delivered by large cap mutual funds. Although historical returns do not guarantee future returns, they tend to give an indication of how different schemes may perform in future. Aside from past returns, other factors which are worth considering by the mutual fund investors include the reputation of the fund house, macro-economic factors, whether the scheme is active or passive and past performance of the fund manager (in case of active scheme), among others. Here we list out some large cap mutual funds which have delivered over 20 percent return in the past 3 years. Those who are not aware, large cap funds refer to the schemes which invest 80 percent of their assets in large cap stocks. Large cap fund 3-year-returns (%) DSP Large Cap Fund 21.84 Edelweiss Large Cap Fund 20.53 HDFC Large Cap 20.14 ICICI Pru Large Cap Fund 21.80 Nippon India Large Cap Fund 23.98 Invesco India Large Cap 21.59 Baroda BNP Paribas Large Cap Fund 20.54 (Source: AMFI; direct returns as on July 11) As one can see in the list above, there are seven large cap mutual funds which have delivered over 20 percent annualised return in the past three years. Nippon India Large Cap Fund delivered 23.98 percent per annum and Invesco India Large Cap Fund gave 21.59 percent per annum. Other schemes which gave over 20 percent return in the past three years include Edelweiss Large Cap Fund and Baroda BNP Paribas Large Cap Fund. Notably, the historical returns do not guarantee a scheme's future returns. This means just because a scheme has delivered exceptional performance in the past three years, it does not mean it will continue to perform at the same pace in future as well. Visit here for all personal finance updates
Time of India
7 days ago
- Time of India
Baroda BNP Paribas Liquid Fund turns Rs 1 lakh investment to nearly Rs 3 lakh in 23 years, AUM crossing Rs 10,000 crore
Live Events Baroda BNP Paribas Mutual Fund has completed 23 years of existence in the industry and has almost tripled investor wealth Rs1 lakh invested at launch to Rs 2,99,565 now and has crossed an AUM of Rs 10,000 crore. Baroda BNP Paribas Liquid Fund is a trusted solution for investors seeking capital protection, liquidity, and stable short-term returns and crossing a significant milestone of the scheme AUM at Rs 10,500 crore in Average Assets Under Management (AUM) Read | Nearly 112 lakh SIPs closed in 2025: Should you worry about the negative net SIP trend? The fund is managed by Vikram Pamnani and Gurvinder Singh Wasan. The performance of the fund is benchmarked against CRISIL Liquid Debt A-I Index. Baroda BNP Paribas Liquid Fund has delivered an annualised return of 7.09% return over the past one month, reaffirming its reputation as a reliable option for managing surplus funds, according to a press global markets experiencing volatility amid geopolitical uncertainty and policy shifts — including U.S. sentiment swings under the Trump era — many investors are adopting a "wait and watch" approach. For those looking to safely park capital while staying liquid, liquid funds present an attractive alternative to traditional savings accounts, the release BNP Paribas Liquid Fund achieves this through prudent investment in short-term debt instruments with minimal price risk and low credit risk. With a modified duration of just 55 days, the fund offers liquidity while aiming to generate returns higher than conventional savings investors seek safety, liquidity, and predictable returns, the Baroda BNP Paribas Liquid Fund continues to stand out as a safe haven for short-term money management, proving its relevance even 23 years Read | Mutual funds slashes cash allocation by Rs 13,000 crore in June; PPFAS and Quant MF join trend Baroda BNP Paribas Liquid Fund is an open-ended liquid scheme with a relatively low interest rate risk and moderate credit risk to the Sebi mandate, liquid funds make investment in debt and money market securities with maturity of up to 91 days only.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
